Long-Term Exposure to Temozolomide Affects Locomotor Activity and Cartilage Structure of Elderly Experimental Rats

Chemotherapy with temozolomide (TMZ) is an essential part of anticancer therapy of various malignant tumours; however, its long-term effects on patients’ health and life quality need to be further investigated. Here, we studied the effects of TMZ and/or companion drug dexamethasone (DXM) on the locomotor activity and cartilage structure of elderly Wistar rats (n = 40). Long-term TMZ treatment selectively inhibited the horizontal, but not vertical locomotor activity of the rats (6.7-fold, p < 0.01) and resulted in delamination of the superficial epiphyseal cartilage of the femoral epiphysis of knee joints, a 2-fold decrease in mean thickness of epiphyseal cartilage (p < 0.001), and changes in the proliferative and maturation cartilage zones ratio. The simultaneous use of DXM attenuated TMZ-induced changes in cartilage thickness and integrity and compensated the decrease in horizontal locomotor activity of experimental animals. Nevertheless, combined TMZ/DXM treatment still significantly affected the structure of proximal tibial, but not distal femoral epiphysis of knee joints of the rats. These changes were accompanied by the increased content of total glycosaminoglycans (GAGs) and their partial re-localisation from chondrocytes into tissue matrix, as well as the decrease in sulfated GAGs content in both compartments. Taken together, the results demonstrate that long-term treatment with TMZ results in a significant decrease in locomotor activity of elderly Wistar rats and the reorganisation of their knee joint cartilage structure, while DXM treatment attenuates those effects. So, use of DXM or chondroprotective drugs might be beneficial to maintain quality of life for TMZ-treated cancer patients.

[1]  Peter M. Klein,et al.  Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy , 2020, Radiation Research.

[2]  A. Russo,et al.  Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. , 2019, European journal of endocrinology.

[3]  V. Chekhonin,et al.  On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance , 2019, Biomedicines.

[4]  A. Grodzinsky,et al.  DEXAMETHASONE: CHONDROPROTECTIVE CORTICOSTEROID OR CATABOLIC KILLER? , 2019, European cells & materials.

[5]  K. Debatin,et al.  Temozolomide and Other Alkylating Agents in Glioblastoma Therapy , 2019, Biomedicines.

[6]  Xiaopeng Song,et al.  A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy , 2018, Journal of cancer research and therapeutics.

[7]  V. Zagonel,et al.  Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study , 2018, American journal of clinical oncology.

[8]  S. Grossman,et al.  Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System. , 2018, Oncology.

[9]  A. R. Pereira-Caixeta,et al.  Inhibiting constitutive neurogenesis compromises long-term social recognition memory , 2018, Neurobiology of Learning and Memory.

[10]  A. V. Suhovskih,et al.  Conventional Anti-glioblastoma Chemotherapy Affects Proteoglycan Composition of Brain Extracellular Matrix in Rat Experimental Model in vivo , 2018, Front. Pharmacol..

[11]  Jinming Yu,et al.  Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases , 2018, Thoracic cancer.

[12]  T. Hirvikoski,et al.  Prenatal dexamethasone treatment in the context of at risk CAH pregnancies: Long-term behavioral and cognitive outcome , 2018, Psychoneuroendocrinology.

[13]  Fahad M. Alshahrani,et al.  Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review , 2017, Hormones.

[14]  C. Pariante,et al.  Depletion of adult neurogenesis using the chemotherapy drug temozolomide in mice induces behavioural and biological changes relevant to depression , 2017, Translational Psychiatry.

[15]  Z. Fu,et al.  Timing of glucocorticoid administration determines severity of lipid metabolism and behavioral effects in rats , 2017, Chronobiology international.

[16]  R. Stupp,et al.  Corticosteroids compromise survival in glioblastoma. , 2016, Brain : a journal of neurology.

[17]  P. Kranke,et al.  Adverse side effects of dexamethasone in surgical patients. , 2015, The Cochrane database of systematic reviews.

[18]  G. Jiang,et al.  Temozolomide for Treating Malignant Melanoma. , 2015, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[19]  R. Przewłocki,et al.  Behavioral and molecular alterations in mice resulting from chronic treatment with dexamethasone: Relevance to depression , 2015, Neuroscience.

[20]  M. Yıldırım,et al.  Evaluation of spatial memory and locomotor activity during hypercortisolism induced by the administration of dexamethasone in adult male rats , 2015, Brain Research.

[21]  P. Menshanov,et al.  Dexamethasone suppresses the locomotor response of neonatal rats to novel environment , 2014, Behavioural Brain Research.

[22]  W. Roa,et al.  Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. , 2014, Current oncology.

[23]  V. De Sanctis,et al.  Temozolomide-Related Hematologic Toxicity , 2013, Oncology Research and Treatment.

[24]  V. Esposito,et al.  Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. , 2013, International journal of radiation oncology, biology, physics.

[25]  Abbas Ali Vafaei,et al.  Peripheral injection of dexamethasone modulates anxiety related behaviors in mice: an interaction with opioidergic neurons. , 2008, Pakistan journal of pharmaceutical sciences.

[26]  G. Tomei,et al.  The safety of the temozolomide in patients with malignant glioma. , 2006, Current drug safety.

[27]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[28]  K. Hess,et al.  Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Hess,et al.  Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? , 2002, Supportive Care in Cancer.

[30]  M. Annefeld,et al.  The mode of action of a glycosaminoglycan-peptide-complex (Rumalon®) on articular cartilage of the rat in vivo , 1987, Clinical Rheumatology.

[31]  H. Schryver,et al.  Morphologic and biochemical changes in cartilage of foals treated with dexamethasone. , 1983, The Cornell veterinarian.

[32]  A. Zarins,et al.  The effect of systemic corticosteroids on rabbit articular cartilage. , 1972, Arthritis and rheumatism.

[33]  M. Nikitović,et al.  Severe hematologic temozolomide-related toxicity and lifethreatening infections. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[34]  M. Becker-Schiebe,et al.  Hematologic Toxicity of Temozolomide and Radiation in Glioblastoma Patients – Correlation with Clinicopathological Factors , 2015 .

[35]  Y. Shu,et al.  Temozolomide for treatment of brain metastases: A review of 21 clinical trials. , 2014, World journal of clinical oncology.

[36]  L. Memış,et al.  The effect of temozolomide on the prevention of epidural fibrosis developing after lumbar laminectomy in rats. , 2012, Turkish neurosurgery.

[37]  T. Hirvikoski,et al.  Long-term outcome of prenatal dexamethasone treatment of 21-hydroxylase deficiency. , 2011, Endocrine development.

[38]  P. Loehrer.  Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma , 2006 .

[39]  A. Podbielski,et al.  Dose related effects of dexamethasone treatment on the ultrastructure of articular cartilage in rats , 2005, Agents and Actions.